While the ideal oral endocrine agent (aromatase inhibitor (AI) or tamoxifen) in HR+/HER2+ breast cancer remains unknown, so does the clinical impact of adding ovarian suppression (OS) in premenopausal women. This evidence concerns the gene ERBB2 and breast carcinoma.